TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro Medicus Limited ( (AU:PME) ) has provided an update.
Pro Medicus Limited has addressed recent speculation regarding a data breach involving Visage Imaging. The company confirmed that an unauthorized access incident occurred in July 2025, affecting a single email inbox, but no client systems or patient data were compromised. The breach was contained, and external cybersecurity experts were engaged. While some personal information of approximately 100 employees might have been accessed, no financial loss or operational impact was reported. Pro Medicus has informed affected individuals and relevant authorities, ensuring compliance with legal obligations.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company, founded in 1983. It provides a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups globally. The company’s Visage 7 suite is known for its ultra-fast, clinically rich, and scalable platform, deployable in both public and private cloud environments. Pro Medicus offers a suite of RIS, PACS, Artificial Intelligence, and e-health solutions, with offices in Melbourne, Berlin, and San Diego.
Average Trading Volume: 175,191
Technical Sentiment Signal: Buy
Current Market Cap: A$27.16B
Learn more about PME stock on TipRanks’ Stock Analysis page.